Navigation Links
Experimental drug shows promise in treating certain lymphomas
Date:4/16/2008

BIRMINGHAM, Ala. - New clinical data showed some cancer patients with recurrent lymphoma benefited from an experimental drug called AME-133v, said a researcher at the University of Alabama at Birmingham (UAB).

The data was presented April 15th during the 2008 annual meeting of the American Association for Cancer Research in San Diego.

Phase 1 clinical trial data showed AME-133v had a potent tumor-halting response in patients with a particular kind of cancer called follicular lymphoma, said Andres Forero, M.D., associate scientist at the UAB Comprehensive Cancer Center and lead presenter on the results.

"These first results suggest that AME-133v provides a mechanism of action that may be more potent and ultimately more effective than the treatments we have on hand," Forero said.

The testing was done in 22 patients treated at UAB and at other locations around the nation. Follicular lymphoma patients are being enrolled in a Phase 2 study.

About 22 percent of the lymphomas in the United States are of the follicular type, according to the American Cancer Society. The malignant cells tend to grow slowly in a circular pattern in the lymph nodes. Follicular lymphoma can be treated with chemotherapy, but the disease often returns after therapy is complete.

Research has shown that a new class of anticancer agents like AME-133v, a class called monoclonal antibodies, can lengthen survival times, Forero said.

In the UAB study, AME-133v was administered in combination with a standard chemotherapy agent sometime after the initial treatments had been given, and after the re-emergence of cancer.

The experimental drug triggered signaling pathways within cells that slow or stop lymphoma cancer's growth, and the drug combo was well-tolerated by the body and caused minimal side effects, Forero said.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Page: 1

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... have until January 15, 2017 to apply for a 2016/2017 California Casualty Thomas ... http://www.calcasathleticsgrant.com . Qualifying schools can receive up to $3,000. , The ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... advisory organization, is proud to announce it has added CXC Solutions (CXC) as ... management solutions. These solutions are tailored to help benefits advisors reduce operating ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... is now offering HIAC particle counting and sizing services for USP 788 and ... instituted the new service as a response to the needs of pharmaceutical and ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the launch of a Kickstarter crowd funding campaign ( http://kck.st/2g3a1so ) for the ... active alerts and even taking an EKG from the watch while sharing these ...
(Date:12/6/2016)... ... December 06, 2016 , ... Keeping Gift Season Safe, In a ... are safe and age-appropriate for their recipients. This is the idea behind Safe Toys ... safety of items that would make good gifts for children. For companies that produce ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016 Eurofins ... accreditation from the College of American Pathologists (CAP) ... (CLIA) for its new laboratory in ... moved its North American headquarters. "Our ... sequencing -- which is still considered the ,Gold ...
(Date:12/6/2016)... Miss. , Dec. 6, 2016 Two ... rescue personnel in a simulated mass casualty event Tuesday ... . The technology debuted before an audience including ... and representatives from Homeland Security, Federal Law Enforcement ... Drone Project, known as HiRO (Health Integrated Rescue Operations), ...
(Date:12/6/2016)...  Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), ... it entered into collaboration with Takeda Pharmaceutical Company ... of NASH and other gastrointestinal (GI) related disorders, ... UNA Oligomer chemistry. The financial terms were not ... and expertise in GI disorders, we are confident ...
Breaking Medicine Technology: